Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apomorphine infusion in advanced Parkinson's Disease
NCT02339064Phase 3Active, not recruiting
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Feb 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of apomorphine in Parkinson's disease (PD), sponsored by Supernus Pharmaceuticals, Inc. Primary endpoint: Percent of daily "off" time during the waking day at 12 weeks. Started Feb 2015; status: active, not recruiting.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02339064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02339064.